Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

This study has been terminated.
(Sponsor discontinued funding of the study)
Sponsor:
Collaborator:
Ortho Biotech, Inc.
Information provided by:
OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier:
NCT00258440
First received: November 23, 2005
Last updated: June 1, 2011
Last verified: June 2011

November 23, 2005
June 1, 2011
May 2003
September 2008   (final data collection date for primary outcome measure)
Number of Subjects That Maintained Target Hemoglobin Level (11-12 g/dL) Maintenance Weekly for 12 Weeks [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00258440 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics (PK) and Pharmacodynamics Assays That Measure Concentration of Erythropoietin in Serum. [ Time Frame: every other week ] [ Designated as safety issue: No ]
  • Quality of Life at Baseline and Weeks 4, 8, 16, 24, and 28 [ Time Frame: weeks 4,8,16,24 and 28 ] [ Designated as safety issue: No ]
  • Number of Adverse Events (AEs) Experienced as Measure of Safety and Tolerability. [ Time Frame: On study, averaging 3 to 6 months. ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
A Pilot Trial of Extended Interval Dosing of Epoetin Alfa (Procrit®) for the Treatment of Anemia in Oncology Patients

RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy. It may also help relieve fatigue in patients with anemia.

PURPOSE: This randomized clinical trial is studying how well epoetin alfa works in treating patients with anemia who are undergoing chemotherapy for cancer.

OBJECTIVES:

Primary

  • Determine the efficacy, in terms of maintenance of target hemoglobin and hematocrit levels, of interval dosing with epoetin alfa in treating patients with anemia undergoing chemotherapy for nonhematologic cancer.

Secondary

  • Determine the pharmacokinetics and pharmacodynamics of this drug in these patients.
  • Correlate hemoglobin and hematocrit response with patient age (> 65 years vs < 65 years) in patients treated with this drug.
  • Determine quality of life of patients treated with this drug.
  • Determine the adverse effects of this drug in these patients.
  • Determine the change over time of symptom and quality of life variables (e.g., fatigue) in patients treated with this drug.

OUTLINE: This is a partially randomized, pilot study. Patients are stratified according to age (< 65 years vs ≥ 65 years). Patients are assigned to 1 of 2 treatment groups based on participation in the pharmacokinetic (PK) portion of the study.

  • Group 1 (PK study, initial therapy): Patients are randomized to 1 of 2 treatment arms.

    • Arm I: Five patients receive epoetin alfa subcutaneously (SC) once weekly. Treatment continues for 24 weeks in the absence of unacceptable toxicity.
    • Arm II: Five patients receive epoetin alfa SC once weekly until hematocrit is > 36% OR hemoglobin reaches a value of 12 g/dL. Patients then proceed to maintenance therapy.

Patients in both arms also undergo PK sampling periodically during study treatment.

  • Group 2 (non-PK study, initial therapy): Fifteen patients receive epoetin alfa SC once weekly until hematocrit is > 36% OR hemoglobin reaches a value of 12 g/dL. Patients then proceed to maintenance therapy.
  • Maintenance therapy: Patients receive epoetin alfa SC once every other week for up to 24 weeks of total treatment (including both initial therapy and maintenance therapy). Patients whose blood counts fall below the critical levels are placed on a weekly dosing schedule. Patients whose blood counts rise too high discontinue study drug until blood counts are reduced.

Quality of life (including fatigue) is assessed at baseline and then every 4 weeks for 28 weeks.

After completion of study therapy, patients are followed at 4 weeks.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
  • Anemia
  • Fatigue
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Drug: Weekly procrit dosing
    The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.
  • Drug: Interval Dosing
    The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.
  • Active Comparator: Weekly Procrit (epoetin alfa) dosing
    Weekly dosing schedule subjects will get the study drug once every week until the end of the study.
    Intervention: Drug: Weekly procrit dosing
  • Experimental: Interval Dosing (epoetin alfa) PK Group
    Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who consented to pharmacokinetic testing
    Intervention: Drug: Interval Dosing
  • Experimental: Interval Dosing (epoetin alfa) Non PK Group
    Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who did not consent to pharmacokinetic testing.
    Intervention: Drug: Interval Dosing
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
7
September 2008
September 2008   (final data collection date for primary outcome measure)

ELIGIBILITY CRITERIA

  • 18 years of age or greater
  • Must have Hb less than 11 g/dl and normal hematopoesis
  • Must have non-myeloid malignancies treated with myelosuppressive therapy *Must have an ECOG performance status of 0-2
  • Must have a life expectancy of 6 months or greater
  • Must have adequate liver function (bilirubin less than or equal to 2.0 mg) and renal function (creatinine less than or equal to 2.0 mg)
  • Must have normal serum folate and vitamin B12 levels or be receiving replacement therapy
  • Must be iron replete (transferring saturation great than or equal to 20 percent and ferritin greater than or equal to 100 mg/ml) or be receiving replacement therapy
  • Must be able to fully comprehend and give written consent.
  • Female patients with reproductive potential must be practicing an effective method of birth control (e.g., abstinence, prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, surgical sterilization) before entry and throughout the study.
  • Female patients with reproductive potential must have a negative serum HCG pregnancy test at screening (within 7 days before the first dose of study drug)

Exclusion criteria

  • Patient has uncontrolled hypertension
  • Patient has history of symptomatic cardiac disease
  • Patient has serious intercurrent illness
  • The patient is pregnant, has a positive serum HCG or is lactating Patient has known hypersensitivity to mammalian cell-derived products or human albumin.
  • Patient has diagnosis of polycythemia vera, chronic myelogenous leukemia, myelodysplastic syndrome
  • May not be due for transplant within 24 weeks
  • Anemia due to factors other than cancer.
  • History of a thrombotic vascular event.
  • History of seizures
  • Patient has received a red blood cell growth factor (epoetin alfa or darbepoetin) within the last 60 days
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00258440
CDR0000445450, OHSU-ONC-03017-LP, OHSU-1616, OHSU-7754, ORTHO-ONC-03017-LP
Yes
Joseph Bubalo, PharmD, BCPS, BCOP, OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Ortho Biotech, Inc.
Principal Investigator: Joseph Bubalo, PharmD, BCPS, BCOP OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP